Streetbeat News

Regulatory

SPY

Atlanta Fed President Bostic stated that the Federal Reserve is working to bring the economy back into a supply-demand balance.

Portfolio Pulse from Benzinga Newsdesk

June 23, 2023 | 12:18 pm

GOOG

GOOGL

META

Meta Platforms plans to end access to news on Facebook and Instagram in Canada once the Online News Act, requiring internet firms to reimburse news publishers, comes into effect. The act forces platforms like Facebook and Google to negotiate commercial deals and pay news publishers for their content.

Portfolio Pulse from Anusuya Lahiri

June 23, 2023 | 12:18 pm

AMLX

Amylyx Pharmaceuticals received a negative opinion from the CHMP on its conditional marketing authorization application for AMX0035, a treatment for ALS in the EU. The company plans to seek re-examination of its application.

Portfolio Pulse from Bill Haddad

June 23, 2023 | 12:15 pm

GILD

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended Gilead Sciences' Trodelvy for pre-treated HR+/HER2- metastatic breast cancer.

Portfolio Pulse from Benzinga Newsdesk

June 23, 2023 | 12:14 pm

JPM

JPMorgan Chase & Co. has agreed to pay a $4 million settlement to the U.S. Securities and Exchange Commission (SEC) for accidentally deleting 47 million electronic messages it was required to keep. The deleted messages could affect future investigations, legal matters, and regulatory inquiries.

Portfolio Pulse from Akanksha Bakshi

June 23, 2023 | 12:08 pm

BRDS

Bird Global, Inc. (NYSE:BRDS) has been awarded a new three-year permit to expand its e-scooter operations in Vienna, Austria. The permit allows Bird to double its fleet size, increase its operational area by 250%, and serve 120% more population. The expansion is based on Bird's focus on safety, sustainability, and technical innovation.

Portfolio Pulse from Benzinga Newsdesk

June 23, 2023 | 12:07 pm

ABBV

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended AbbVie's Atogepant for the prophylaxis of migraine in adults with four or more migraine days per month.

Portfolio Pulse from Benzinga Newsdesk

June 23, 2023 | 12:06 pm

SONN

Sonnet BioTherapeutics announced presentations at the 2023 Cytokine-Based Drug Development Summit and provided a preliminary update on the SON-080 study in chemotherapy-induced peripheral neuropathy. Seven patients have been enrolled, and doses have been tolerated well. The Data Safety Monitoring Board is expected to meet in Q3 2023.

Portfolio Pulse from Benzinga Newsdesk

June 23, 2023 | 12:05 pm

OCEA

Ocean Biomedical has extended its patent rights for a breakthrough idiopathic pulmonary fibrosis (IPF) discovery to Europe.

Portfolio Pulse from Bill Haddad

June 23, 2023 | 12:02 pm

AACI

Rezolve AI Limited has filed a registration statement on Form F-4 to become publicly traded in connection with its proposed business combination with Armada Acquisition Corp. I (AACI).

Portfolio Pulse from Bill Haddad

June 23, 2023 | 12:01 pm